






































Repeat testing of low-level HIV-1 RNA: assay 
performance and implementation in clinical trials
Kirsten Whitea, Will Garnera, Lilian Weia, Joseph J. Eronb, Lijie Zhonga,
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Cecilia Tran-Muchowskia, Kim Lindstroma, James Portera,
David Piontkowskya, Angela Lightc, Heinz Reiskec and Erin Quirka
Objective: Assess the performance of HIV-1 RNA repeat testing of stored samples in
cases of low-level viremia during clinical trials.
Design: Prospective and retrospective analysis of randomized clinical trial samples and
reference standards.
Methods: To evaluate assay variability of the Cobas AmpliPrep/Cobas TaqMan HIV-1
Test, v2.0, three separate sources of samples were utilized: the World Health Organi-
zation (WHO) HIV reference standard (assayed using 50 independent measurements at
six viral loads <200 copies/ml), retrospective analysis of four to six aliquots of plasma
samples from four clinical trial participants, and prospective repeat testing of 120
samples from participants in randomized trials with low-level viremia.
Results: The TaqMan assay on the WHO HIV-1 RNA standards at viral loads<200 cop-
copies/ml performed within the expected variability according to assay specifications.
However, standards with low viral loads of 36 and 18 copies/ml reported values of
 50 copies/ml in 66 and 18% of tests, respectively. In participants treated with
antiretrovirals who had unexpected viremia of 50–200 copies/ml after achieving
<50 copies/ml, retesting of multiple aliquots of stored plasma found <50 copies/ml
in nearly all cases upon retesting (14/15; 93%). Repeat testing was prospectively
implemented in four clinical trials for all samples with virologic rebound of 50–
200 copies/ml (n¼120 samples from 92 participants) from which 42% (50/120) had
a retest result of less than 50 copies/ml and 58% (70/120) retested  50 copies/ml.
Conclusion: The TaqMan HIV-1 RNA assay shows variability around 50 copies/ml that
affects clinical trial results and may impact clinical practice. In participants with a
history of viral load suppression, unexpected low-level viremia may be because of assay
variability rather than low drug adherence or true virologic failure. Retesting a stored
aliquot of the same sample may differentiate between assay variability and virologic
failure as the source of viremia. This retesting strategy could save time, money, and
anxiety for patients and their providers, as well as decrease follow-up clinic visits
without increasing the risk of virologic failure and resistance development.
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Introduction
Virologic success for HIV-1 treatment is the achievement
and life-long maintenance of undetectable HIV-1 RNA,
often defined as less than 50 copies/ml [1–3]. All
biological assays, including quantification of HIV-1
RNA, show variability in the reported results. Although
virologic failure is defined by HIV treatment guide-
lines as confirmed by HIV-1 RNA greater than
200 copies/ml, considerable uncertainty exists about
the clinical significance of HIV-1 RNA between
50 copies/ml and 200 copies/ml [3]. In clinical practice,
after achieving less than 50 copies/ml, an HIV-1 RNA
value  50 copies/ml may trigger a follow-up clinic
visit with an additional blood draw, and, if confirmed,
more frequent monitoring of HIV-1 RNA or a change in
antiretroviral regimen. For people living with HIV-1, a
report of being ‘detectable’ may cause substantial anxiety.
In the context of clinical trials of HIV-1 treatment,
primary efficacy endpoints for many studies are based
on the United States Food and Drug Administration
snapshot (US FDA)-defined snapshot algorithm for
the last available and often single viral load result
obtained in the visit window – generally Week 48 for
studies of treatment-naı̈ve participants [4]. In the
simplest interpretation of this analysis, there are three
possible outcomes: HIV-1 RNA less than 50 copies/ml,
 50 copies/ml, and no data in the window. Current
trials of HIV-1 result in high efficacy rates and the
outcomes of a few participants can influence the
interpretation of antiretroviral efficacy. For example, a
participant with a viral load of 51 copies/ml is classified as
HIV-1 RNA 50 copies/ml (virologic failure), whereas
another with 49 copies/ml is classified as less than
50 copies/ml (virologic success). In cases of HIV-1 RNA
 50 copies/ml in clinical trials, current practice is to
perform an unscheduled retest visit after adherence
counseling. If the retest visit viral load is less than
50 copies/ml and is within the visit window, then that last
result is considered the final snapshot result.
Our hypothesis was that for some participants who
achieved an HIV-1 RNA level less than 50 copies/ml on
therapy, subsequent values  50 copies/ml but less than
200 copies/ml are because of assay variation rather than
true virologic failure. Repeat viral RNA testing of an
aliquot of plasma stored from the original blood draw
could prevent additional follow-up clinic visits and blood
sampling. This is supported by current FDA guidance
that suggests that repeat testing of the same sample with
an initial  50 copies/ml result may retest as less than
50 copies/ml [5] and eliminate a virologic failure
assessment caused by a variety of reasons, including
assay variability. Here, we present an analysis of assay
variability using reference standards and clinical trial
samples with low-level viremia and report the outcomes
of implementing this strategy prospectively in clinical
trials.
Methods
All HIV-1 RNA quantification results in this report were
obtained with the Cobas AmpliPrep/Cobas TaqMan v2.0
HIV-1 assay [6] (Roche Diagnostics, Indianapolis,
Indiana, USA) and were performed at Covance labora-
tories in Indianapolis, Indiana; Geneva, Switzerland; and
Singapore, Malaysia. The manufacturer’s lower limit of
quantification (LLOQ) and lower limit of detection
(LOD) is 20 copies/ml of HIV-1 RNA. The WHO HIV
2nd International Standard (97/650) for HIV-1 RNA
quantification [7] was diluted in HIV-1 negative
ethylenediaminetetraacetic acid (EDTA) plasma to cover
the lower range of viral loads of the assay. At each WHO
standard dilution, 50 individual aliquots were frozen and
tested on independent assay runs at the Indianapolis site
(n¼ 20), Geneva site (n¼ 20), and Singapore site
(n¼ 10). The functional sensitivity (LLOQ) was con-
firmed by the lowest concentration that did not exceed a
20% coefficient of variation (CV; results in log10). The
LOD was confirmed by the lowest concentration that
showed 95% positivity (HIV-1 RNA detected).
In an initial assessment, four to six aliquots of plasma
were obtained from four HIV-1 infected participants
(15 samples) enrolled in studies GS-US-141-1475
(NCT02397694) and GS-US-380-1844 (NCT02603120)
[8]. Plasma samples were obtained, divided into aliquots,
frozen on dry ice, and shipped to Covance Central
Laboratories. The first HIV-1 RNA result was obtained
during the course of the study followed by later testing of
HIV-1 RNA from previously unthawed aliquots tested in
parallel. Following the analysis of samples from the initial four
participants, 120 additional samples from 92 participants were
prospectively assessed during the conduct of clinical studies
GS-US-380-1489 (NCT02607930), GS-US-380-1490
(NCT02607956), GS-US-380-1844, and GS-US-380-
1878 (NCT02603107) in which repeat testing was
performed on previously unthawed samples in cases of
HIV-1 RNA 50 – 200copies/ml after achieving less than
50copies/ml. Exact confidence interval (CI) was obtained
using Blaker’s method.
Results and Discussion
To quantify the variability of the TaqMan v2.0 HIV-1
assay at low viral loads, six standards with estimated HIV-1
RNA copy numbers of 142, 71, 36, 18, 9, and 4 copies/
ml were generated by dilution of the WHO 2nd HIV
International Standard. Fifty aliquots of each sample
were analyzed (Fig. 1). Overall, the results fell within
the manufacturer’s specified LLOQ and LOD and the
variability in the results was as expected for a biological
assay. At the two highest HIV-1 RNA standard
concentrations of 142 and 71 copies/ml, 98% of samples
reported HIV-1 RNA values greater than 50 copies/ml.
For the 142 copies/ml standard, the mean value was
180 copies/ml (range 76–372 copies/ml). For the
71 copies/ml standard, the mean value was 99 copies/
ml (range 43–180 copies/ml). Whenever we tested the
standards with estimated HIV-1 RNA levels of 36 and
18 copies/ml, we obtained values of 50 copies/ml in 66
and 18% of the tests, respectively. At the two lowest
standard concentrations of 9 and 4 copies/ml, 100% of
the samples reported HIV-1 RNA values 50 copies/ml
or less.
If applied to clinical samples, a single HIV-1 RNA
measurement for participants with virologic rebound and
HIV-1 RNA  200 copies/ml or suppression with a low
viral load set point of less than 10 copies/ml should
provide a clinically correct result (e.g. 50 copies/ml
whenever the real value was greater than 200 copies/ml
or less than 50 copies/ml whenever the patient is
suppressed). However, if the true HIV-1 RNA value is
close to the cut-off of less than 50 copies/ml, a single assay
may frequently result as  50 copies/ml because of assay
variability and potentially be clinically misleading.
To explore the HIV-1 RNA assay variability near
50 copies/ml in HIV-1 infected and antiretroviral-treated
clinical trial participants, we selected four study
participants with one or more HIV-1 RNA results less
than 50 copies/ml who subsequently had low-level
viremia and had additional stored and previously
unthawed aliquots of frozen plasma available for repeat
testing (Fig. 2a–d). Altogether, in participants having
unexpected viremia 50 copies/ml, retesting of multiple
aliquots of stored plasma found less than 50 copies/ml in
nearly all cases (14/15 aliquots; 93%).
We implemented a repeat testing algorithm for partici-
pants with prior suppression of HIV-1 RNA less than
50 copies/ml and virologic rebound between 50 and
200 copies/ml. Specifically, one aliquot of stored plasma
was automatically repeat tested by the reference
laboratory. The upper limit of 200 copies/ml for this
repeat testing was based on the AIDS Clinical Trials
Group and the US Department of Health and Human
Services guidelines for defining rebound and trig-
gering participant management decisions [3,9,10] and
protocol-defined resistance testing if HIV-1 RNA is
 200 copies/ml. The samples were required to have
been stored frozen and not previously thawed because
HIV-1 RNA is stable if properly stored at 70 8C but is
subject to degradation after either long-term storage or
multiple freeze–thaw cycles resulting in incorrect
reporting of a lower viral load [11,12].
The prospective analysis had repeat HIV-1 RNA testing
performed on 120 sample sets from 92 HIV-1 infected
participants from four clinical trials of treatment-naı̈ve or
suppressed switch designs (Fig. 2e). Among these sample
sets, the initial HIV-1 RNA results consisted of 91
samples with HIV-1 RNA of 50–100 copies/ml and 29
samples with 101–200 copies/ml. The repeat results of
HIV-1 RNA less than 50 copies/ml were reported for
50 samples (50/120; 42%; 95% CI 33–51%). Of these 50
samples, the initial HIV-1 RNA was between 50 and
100 copies/ml in all but one sample set (49/50; 98%). Of
those samples with a repeat test result  50 copies/ml,
87% (61/70) had follow-up data from subsequent visits
and 92% (56/61) resuppressed to HIV-1 RNA less than
50 copies/ml. 5.7% (4/70) of the sample sets were from
three participants who later qualified for resistance
testing; none had emergent drug resistance.
Overall, the results presented here yield useful information
on the variability of results of the Cobas AmpliPrep/Cobas
TaqMan v2.0 HIV-1 assay below 200 copies/ml and
highlight the challenges of achieving and maintaining
a strict clinical endpoint of HIV-1 RNA less than
50 copies/ml. We implemented a repeat HIV-1 RNA-
testing protocol utilizing stored samples from the original
blood draw and found that more than half (54%; 49/91
samples) of samples with 50–100 copies/ml of HIV-1 RNA
repeated as less than 50 copies/ml. These data support the
FDA guidance on repeat testing of the same sample to
distinguish true virologic failures from other reasons of
failure such as assay variability. One limitation of this study is
that most participants were taking an antiretroviral regimen
consisting of an integrase strands transfer inhibitor with a
high barrier to resistance (bictegravir or dolutegravir) in
combination with two nucleos(t)ide reverse transcriptase
inhibitors, thus reducing its generalizability to other
regimens or participant populations. Further discussion of
data variability amongst clinicians, people living with HIV,
and researchers should lead to guidance on how to best
manage low-level rebound.
Fig. 1. HIV-1 RNA results of 50 replicates of each dilution of
the WHO standard tested at three Covance laboratories by
the TaqMan 2.0 assay. The second WHO standard of HIV-1
RNA was diluted and stored in 50 tubes, frozen, shipped as
needed on dry ice, assayed, and results from each measure-
ment are plotted for each dilution. The 50 copies/ml threshold
for participant management decisions is shown in the gray
dotted line. Results were within the expected specifications of
the assay. WHO, World Health Organization.
Fig. 2. HIV-1 RNA repeat testing results for participants on antiretroviral therapy by the TaqMan 2.0 assay. HIV-1 RNA tests and 
retrospective repeat tests from four participants previously naive to antiretroviral therapy (a–c) or suppressed on antiretroviral 
therapy (d). At baseline and weeks 4, 8, 12, 24, 36, and 48, HIV-1 RNA was measured by TaqMan 2.0. Samples representing viral 
load blips or suspected blips were retested from stored aliquots. Repeat results are shown as open symbols and original results are 
shown as filled circles. The clinical cut-off for virologic failure or success is shown at 50 copies/ml (dotted line). (e) Prospective 
HIV-1 RNA repeat testing of 120 samples. The initial HIV-1 RNA result of 50 – 200 copies/ml (x-axis) and repeat test result (y-axis). 
Reference lines at 50 copies/ml for both axes are shown and the dashed line is the 458 line of equality.
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